Association study of aromatase inhibitors and adverse events related to osteoporosis: based on pharmacovigilance data
Abstract
The association between long-term aromatase inhibitor (AI) use and osteoporosis remains controversial. Clarifying this relationship is critical for optimizing the safety of breast cancer survivors. This study collected publicly available data from Q1 2005 through Q1 2025 in the FAERS database. Three types of AIs were included in the study, and adverse events were restricted to the " Primary Suspect". The narrow definition of "osteoporosis/osteopenia" in the MedDRA Standard query (SMQ) was used for case screening. Additionally, to investigate adverse outcomes related to osteoporosis, we used vertebral compression fractures-the most typical fracture type in osteoporosis-to explore potential severe outcomes that may occur following drug administration. Disproportionality analysis utilized reporting odds ratio (ROR), PRR, IC, and EBGM. Positive signals were defined only when meeting criteria for all four algorithms. Subgroup and Weibull distribution analyses were performed to assess onset time. A total of 19,590 AIs related adverse event reports were extracted during the monitoring period, of which 665 were osteoporosis-related events, and the patients were mainly women aged 65 years and older. At the system-organ class (SOC) level, musculoskeletal system showed a strongest positive signal. At the SMQ level, anastrozole and letrozole showed significant positive signals associated with osteoporosis. In contrast, exemestane did not reach statistical significance. Similarly,…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.